CN102727581A - Pharmaceutical composition with wound repairing effect - Google Patents
Pharmaceutical composition with wound repairing effect Download PDFInfo
- Publication number
- CN102727581A CN102727581A CN2011100908785A CN201110090878A CN102727581A CN 102727581 A CN102727581 A CN 102727581A CN 2011100908785 A CN2011100908785 A CN 2011100908785A CN 201110090878 A CN201110090878 A CN 201110090878A CN 102727581 A CN102727581 A CN 102727581A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- wound
- oligochitosan
- folium artemisiae
- artemisiae argyi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition with a wound repairing effect. The active ingredients of the pharmaceutical composition comprise, by weight: 2g-8g of chitosan oligosaccharides, 0.5g-2g of Salvia Miltiorrhiza, 0.2g-1g of Angelica, and 0.5g-1.3g of folium artemisiae argyi. The pharmaceutical composition is applied to wound repairing tests, and results show that wounds generally heal, and no obvious scar is left. Cell proliferation tests prove that the pharmaceutical composition has good proliferation and regeneration functions on cells. After acute toxicity tests of the pharmaceutical composition performed by the inventor of the invention, the tested pharmaceutical composition can be judged non-toxic according to acute toxicity grading standards. Therefore, the pharmaceutical composition of the invention can be used for treating bedsores, normal wound healing, surgical wound healing, burns, and scalds, and boasts a great clinical value.
Description
Technical field
The present invention relates to pharmaceutical composition, be specifically related to a kind of pharmaceutical composition that wound is had repair.
Background technology
At present, based on research, reported that it has antibiotic, antitumor, accent blood fat, regulates immunity and promotes multiple functions such as wound repair to oligochitosan.Because the oligochitosan pair cell has good affinity, oligochitosan itself is exactly the indispensable composition in the sugar chain structure of cell membrane top layer, plays iuntercellular identification in vivo, regulation and control, and information is passed on, effects such as contact inhibition.And the structure of oligochitosan and cell are closely similar; And can act directly on the cell through experiment proof oligochitosan, play the effect of good reparation damaged cell, and can recover the function of cell; Promote the growth of granulation tissue, and then promote the healing of wound.
But the inventor finds that when using oligochitosan that wound is treated separately, its effect is not very remarkable.The present invention is used with certain proportion through with Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Folium Artemisiae Argyi and oligochitosan, processes new drug regimen, and through cell experiment, zoopery and clinical experiment prove that it has the repair of strong effect to wound.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, and research design contains the pharmaceutical composition of oligochitosan, strengthens the wound repair effect.
The invention provides a kind of pharmaceutical composition that wound is had repair.
Pharmaceutical composition of the present invention is made up of following components by weight ratio:
Oligochitosan 2g-8g, Radix Salviae Miltiorrhizae extract 0.5g-2g, eumenol 0.2g-1g, Folium Artemisiae Argyi extract 0.5g-1.3g.
Pharmaceutical composition of the present invention preferably is made up of following components by weight ratio:
Oligochitosan 5g, Radix Salviae Miltiorrhizae extract 1g, eumenol 0.65g, Folium Artemisiae Argyi extract 0.8g.
Pharmaceutical composition of the present invention makes through following method:
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram then, boil 5min, be cooled to room temperature then, cross and filter out insoluble matter, promptly get.
Pharmaceutical composition of the present invention can be prepared into spray or liniment.
Each composition raw material of pharmaceutical composition of the present invention all can commercially availablely obtain.
The inventor has carried out the wound repair experiment to aforementioned pharmaceutical compositions, and the result shows that wound surface heals basically, does not have obvious cicatrix.Cell proliferation test proves that the propagation of drug regimen pair cell and regeneration function are good.The inventor has carried out the acute toxicity test of aforementioned pharmaceutical compositions, shows according to acute toxicity grading criteria to judge, originally receives the reagent thing to can be considered nontoxic.
Therefore, pharmaceutical composition of the present invention is used to treat healing, the healing of surgical wound, burn, the scald of decubital ulcer, common wound.
The specific embodiment
Embodiment 1 pharmaceutical compositions
Each composition raw material of pharmaceutical composition all can commercially availablely obtain.
Oligochitosan purity＞98% degree of polymerization＜10
The total ketone content of Radix Salviae Miltiorrhizae extract Radix Salviae Miltiorrhizae＞98%
Eumenol lactone content 1%, ferulic acid 0.8%
The use part of Folium Artemisiae Argyi extract brown ceramic powder, 10: 1 plants: leaf, loss on drying＜5%, ash＜3.5%, heavy metal＜10PPM, pesticide residues＜2PPM, total amount of bacteria＜1000CFU/gm.
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram then; Boil 5min; Be cooled to room temperature (25 ℃) then, cross and filter out insoluble matter, promptly get liniment.
The pharmaceutical composition that embodiment 1 makes is used for following test.
Embodiment 2 acute toxicity tests
Experimental animal: 70 of kunming mices, body weight 17-22g, male and female half and half.Available from Shanghai Si Kelai laboratory animal Co., Ltd.
Animal divides into groups: adopt the male and female balanced at random method of dividision into groups respectively, being divided into is 7 groups, and 10 every group, wherein one group is the blank group.
Dosage is confirmed: metering is designed to 3ml/kg (clinical design dosage), 10ml/kg, 50ml/kg, 100ml.
Administration: disposable gastric infusion: before the administration fasting 3-5 hour, after the administration fasting 1-2 hour, water was can't help in fasting.Adopt administration in batches, negative control group, 3ml/kg, first administration of 5.0ml/kg confirms after the administration that set dosage is suitable, gives 10ml/kg and 10.0ml/kg again.Observe continuously after the administration more than 7 days, each observation of every day at upper and lower noon was subsequently once observed 14 days continuously.Itemized record each item observation index.
| Group | Dosage ml/kg | Quantity | Survival rate % |
| 1 | 10 | 100 | |
| 2 | 3 | 10 | 100 |
| 3 | 10 | 10 | 100 |
| 4 | 50 | 10 | 100 |
| 5 | 100 | 10 | 100 |
Conclusion: (solid drugs that is equivalent to 7.45g/kg) do not occur dead when being tried thing gastric infusion dosage reaching 100ml/kg in this test.Judge according to acute toxicity grading criteria, originally receive the reagent thing to can be considered nontoxic.
The test of embodiment 3 wound repair
Experimental animal: the C57 mice, 16-18g, male, available from Shanghai Si Kelai laboratory animal Co., Ltd.
Test method: test mice is divided into blank control group, matched group 1 (U.S. 3M medical adhesive tape), matched group 2 (Britain executes expensive precious Convatee product), matched group 3 (golden English peptide EGF), experimental group, 20 every group.The modeling of mouse back QUMAO otch, wound surface is used iodophor disinfection, uses an amount of normal saline debridement then, then at surface coverage matched group 1 product, matched group 2 products; Spraying matched group 3 products and experimental group medicine, natural drying covers with sterile gauze at last.Wound recovery situation with regard to 3 days, 7 days and 14 days contrasts respectively.Result such as following table:
Embodiment 4 cell proliferation tests
Cell strain: people's epidermis protein cell strain colo-16
Reagent: culture medium: DMEM contains 10% hyclone, 100 μ g/ml penicillins, the streptomycin of 100 μ g/ml; MTT uses the preceding solution that is made into 5mg/ml concentration with the PBS of PH 7.2; DMSO inoculates epidermis cell: when the colo-16 cell of cultivation is grown near monolayer; Draw and go up feelings liquid in the bottle, use 0.3% trypsinization, add an amount of DMEM and process the cell monolayer suspension; Be inoculated in 96 orifice plates, every hole 200 μ L put 37 degree, 5% CO2 gas incubator and cultivate.
Drug treating: inoculate after 24 hours, draw each hole supernatant and reach not attached cell, add matched group 1 (the peace skin relaxes) respectively, matched group 2 (golden English peptide EGF) after the experimental group dosing, continues to cultivate 3 days, and observation of cell is bred situation under inverted microscope.
| Group | Cell proliferation OD value |
| Matched group 1 | 0.15±0.021 |
| Matched group 2 | 0.17±0.045 |
| Experimental group | 0.38±0.088 |
The result: the propagation and the regeneration function of pharmaceutical composition pair cell are good.
Claims (4)
1. one kind has the pharmaceutical composition of repair to wound, it is characterized in that said pharmaceutical composition is made up of following components by weight ratio: oligochitosan 2g-8g, Radix Salviae Miltiorrhizae extract 0.5g-2g, eumenol 0.2g-1g, Folium Artemisiae Argyi extract 0.5g-1.3g.
2. one kind has the pharmaceutical composition of repair to wound, it is characterized in that said active ingredient in pharmaceutical is made up of following components by weight ratio: oligochitosan 5g, Radix Salviae Miltiorrhizae extract 1g, eumenol 0.65g, Folium Artemisiae Argyi extract 0.8g.
3. pharmaceutical composition according to claim 1 and 2 is characterized in that, said pharmaceutical composition prepares through following method:
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add the Folium Artemisiae Argyi extract of 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol and 0.8 gram then, boil 5min, be cooled to room temperature then, cross and filter out insoluble matter, promptly get liniment.
4. pharmaceutical composition according to claim 1 and 2 is characterized in that, said pharmaceutical composition is spray or liniment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110090878.5A CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110090878.5A CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102727581A true CN102727581A (en) | 2012-10-17 |
| CN102727581B CN102727581B (en) | 2016-02-10 |
Family
ID=46984345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110090878.5A Active CN102727581B (en) | 2011-04-11 | 2011-04-11 | A kind of pharmaceutical composition wound to repair |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727581B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2538580A (en) * | 2014-12-03 | 2016-11-23 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| CN107773687A (en) * | 2016-08-30 | 2018-03-09 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat burn and scald |
| CN111729041A (en) * | 2020-07-16 | 2020-10-02 | 张勇 | A Chinese medicinal composition for treating burn and scald, and its preparation method |
| CN111840499A (en) * | 2019-04-01 | 2020-10-30 | 鄂州职业大学 | Warm moxibustion bag for preventing pressure sores and preparation method thereof |
-
2011
- 2011-04-11 CN CN201110090878.5A patent/CN102727581B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 任敬等: ""中药抗感染洗剂治疗骨外伤性创面感染57例"", 《陕西中医学院学报》 * |
| 高维等: ""低分子量壳聚糖的制备及其应用研究"", 《武汉工业学院学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2538580A (en) * | 2014-12-03 | 2016-11-23 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| GB2538580B (en) * | 2014-12-03 | 2019-07-24 | Phynova Ltd | A plant extract and compounds for use in wound healing |
| CN107773687A (en) * | 2016-08-30 | 2018-03-09 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat burn and scald |
| CN111840499A (en) * | 2019-04-01 | 2020-10-30 | 鄂州职业大学 | Warm moxibustion bag for preventing pressure sores and preparation method thereof |
| CN111840499B (en) * | 2019-04-01 | 2022-05-31 | 鄂州职业大学 | Warm moxibustion bag for preventing pressure sores and preparation method thereof |
| CN111729041A (en) * | 2020-07-16 | 2020-10-02 | 张勇 | A Chinese medicinal composition for treating burn and scald, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102727581B (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN106265822A (en) | There are anti-inflammation raw myofunctional Mahonia bealei (Fort.) Carr. extract, preparation method and applications | |
| CN102727581A (en) | Pharmaceutical composition with wound repairing effect | |
| CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
| CN102727579A (en) | Pharmaceutical composition for treatment of oral ulcers | |
| CN103830301A (en) | Flos chrysanthemi with liver tonifying function and application thereof | |
| CN102657712A (en) | Preparation method for adonis coerulea maxim extract and application thereof | |
| CN104971161A (en) | Application of vine tea extract in treatment of acnes | |
| CN102406858B (en) | Disinfection antibacterial agent | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations | |
| CN107468715A (en) | Bacillus cercus CGMCC0601 zymotic fluids are preparing the application in treating diabetes trauma Wound medicine | |
| CN103494932A (en) | Houttuynia cordata scalding spray film agent and preparation method thereof | |
| CN102727578A (en) | Pharmaceutical composition for healing wounds generated by chemoradiotherapy | |
| Xu et al. | Application of Atractylodes Macrocephala Koidz Extract in Methicillin-Resistant Staphylococcus Aureus | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN112168929A (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN105497460A (en) | Disinfectant for disinfecting skins | |
| CN104825744A (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel | |
| CN109999086A (en) | Treat pig polyserositis and arthritic Chinese medicine composition and preparation method thereof | |
| WO2006053487A1 (en) | The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv) | |
| CN109248219A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment brickpox | |
| CN102727580B (en) | A kind of pharmaceutical composition foot wounds to repair | |
| CN107789480A (en) | A kind of pharmaceutical composition for being used to treat canker sore | |
| CN104212723B (en) | One strain Herba Artemisiae Japonicae Nei Shengyouwei can intend dish stey and application thereof | |
| CN102416087A (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method as well as application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |